Figure 1) illustrates the impact on yields when challenging transgenes are suppressed during production in suspension adapted HEK293 host line. In this case transgene was Receptor-Interacting Protein Kinase 3 (RIP3), associated with necrotic cell death.
Our Vectonize technology can be easily integrated into existing platforms and processes or used with our HEKcellence expression platform.
If you'd like to learn more, register your interest in our beta program below.
HEKcellence expression platform
Providing the foundation to our AAV production platform is our HEKcellence™ expression system.
- Suspension-adapted HEK293 cells with full traceability
- Complete with plasmid kits available for different serotypes and associated protocols
- Adaptable to different processes
- Flexible license agreement that's portable to preferred CDMO partners
Our in-house data shows the HEKcellence expression platform can produce higher quality vectors by increasing the proportion with full payloads, providing a route to lower dose requirements and ultimately reduced treatment costs and improved drug safety profiles.
Figure 2a) Compares titre and % full ratio between HEKcellence and leading alternative platform.
2b) illustrates the consistent performance of HEKcellence across different serotypes & with large cargo sizes
Register for our beta program to discover what the HEKcellence platform can do for you.
Join our beta program
We invite you to participate in our beta testing program for the Vectonize and HEKcellence AAV production platform. After registering your interest, our team will contact you to provide more information, outline our commitments to you as a participant and what we expect from you.
Together, we can improve the manufacturability of gene therapies and help transform human health.
The Vectonize™ technology and HEKcellence™ platform are available for research, clinical, and commercialization applications, including services, under specific limited licenses from Revvity.
HEK293 cells are under license from Advec Inc
